ReviewMini reviews in medicinal chemistry2024
Recent Advances in Xanthine Oxidase Inhibitors.
Review in Mini reviews in medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Structural divergence of lentinula edodes polysaccharides is associated with distinct anti-hyperuricemia pathways.NPJ science of food · 2026Article
- Comprehensive phytochemical profiling of dealcoholized zhuyeqing liquor extract and its protective effect on hyperuricemia by regulating urate transporters and LPS/NLRP3 inflammasome pathway.Frontiers in nutrition · 2026Article
- Uricolysis by Arthrobacter globiformis uricase: structural basis for its catalytic activity and thermostability.Acta pharmacologica Sinica · 2025Article
- Effect of encapsulatedVeterinary and animal science · 2025Article
- Molecular mechanisms of urate transport by the native human URAT1 and its inhibition by anti-gout drugs.Cell discovery · 2025Article
- Article
- Article
- Bioassay-Guided Isolation and Identification of Xanthine Oxidase Inhibitory Constituents from the Fruits ofMolecules (Basel, Switzerland) · 2024Article
- Spectroscopic Relationship between XOD and TAOZHI Total Polyphenols Based on Chemometrics and Molecular Docking Techniques.Molecules (Basel, Switzerland) · 2024Article
- Gut microecology: effective targets for natural products to modulate uric acid metabolism.Frontiers in pharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Uric acid is a product of purine nucleotide metabolism, and high concentrations of uric acid can lead to hyperuricemia, gout and other related diseases. Xanthine oxidase, the only enzyme that catalyzes xanthine and hypoxanthine into uric acid, has become a target for drug development against hyperuricemia and gout. Inhibition of xanthine oxidase can reduce the production of uric acid, so xanthine oxidase inhibitors are used to treat hyperuricemia and related diseases, including gout. In recent years, researchers have obtained new xanthine oxidase inhibitors through drug design, synthesis, or separation of natural products. This paper summarizes the research on xanthine oxidase inhibitors since 2015, mainly including natural products, pyrimidine derivatives, triazole derivatives, isonicotinamide derivatives, chalcone derivatives, furan derivatives, coumarin derivatives, pyrazole derivatives, and imidazole derivatives, hoping to provide valuable information for the research and development of novel xanthine oxidase inhibitors.
Indexed as
Identifiers
37711003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.